title: The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma.
abstract: BACKGROUND
  Since IgE is considered to play a crucial role in allergic immune responses, the reduction of free IgE level has been an attractive target in the treatment of allergic diseases. The present study was conducted to determine the effects of a 6-month treatment with different doses of inhaled budesonide and montelukast sodium in children with newly diagnosed atopic asthma.
  
  
  METHODS
  In this randomized, double-blind, double-dummy trial, 51 children with newly diagnosed asthma and sensitivity to house-dust mites were randomly allocated to receive budesonide (in two different doses 400 or 800 mcg) or montelukast for 6 months. The primary end point was the level of serum total and specific IgE before and after treatment. The secondary end points were clinical parameters and forced expiratory volume in 1s (FEV1).
  
  
  RESULTS
  After 6 months of treatment, a high dose of inhaled corticosteroid and montelukast, significantly decreased levels of total and specific IgE. Medium dose of inhaled corticosteroid had no effect on total and specific IgE serum level. Clinical score and FEV1 significantly improved after 6 months of treatment with medium (P = 0.002) and high dose (P = 0.001) of inhaled budesonide and montelukast (P = 0.002). There were no differences between groups in changes of all clinical parameters after treatment.
  
  
  CONCLUSIONS
  Only high doses of inhaled corticosteroids and montelukast decreased the serum IgE levels. Perhaps long-term treatment with montelukast will be beneficial to asthma patients by decreasing IgE levels.
authors.affiliation: The M Curie Hospital, Department of Pediatrics and Allergy, Zgierz, Poland. interna@wss.zgierz.pl
authors.forename: Iwona
authors.initials: I
authors.lastname: Stelmach
authors.forename: Monika
authors.initials: M
authors.lastname: Bobrowska-Korzeniowska
authors.forename: Paweł
authors.initials: P
authors.lastname: Majak
authors.forename: Włodzimierz
authors.initials: W
authors.lastname: Stelmach
authors.forename: Piotr
authors.initials: P
authors.lastname: Kuna
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000280:Administration, Inhalation; D000284:Administration, Oral; D000293:Adolescent; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D039741:Antigens, Dermatophagoides / Q000276:immunology; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D008297:Male; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013440:Sulfides; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D039741:Antigens, Dermatophagoides; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D007073:Immunoglobulin E; D019819:Budesonide; C093875:montelukast